Document registry — page 41
Every document the Institute has published, 1,621 in total, with its identifier, type, certainty rating and review date.
Documents
-
Randomised, double-blind, placebo-controlled, phase 3 study of Pramlintide in type 1 diabetes (adjunct) randomising 480 participants over 52 weeks. Primary result: A…
Moderate01 May 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low01 May 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low01 May 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low01 May 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Thymosin alpha-1 in immune modulation over 8 weeks. Primary result: Higher antibody titres reported…
Moderate30 Apr 2023 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in type 2 diabetes and cardiovascular over as stated in the parent protocol. The Institute holds no reported primary…
Very low30 Apr 2023 -
Phase 1 ascending dose, phase 1 study of Teduglutide in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low28 Apr 2023 -
Randomised crossover, phase 1 study of Semaglutide in adolescent obesity over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low27 Apr 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of CagriSema (cagrilintide with semaglutide) in type 2 diabetes and obesity over as stated in the parent…
Very low27 Apr 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low26 Apr 2023 -
Phase 1 ascending dose, phase 1 study of Larazotide acetate in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low21 Apr 2023 -
Randomised, open-label, active-controlled, phase 3 study of Tirzepatide in type 2 diabetes and cardiovascular randomising 2,002 participants over median 85 weeks…
High20 Apr 2023 -
Randomised, open-label, active-controlled, phase 3 study of Dulaglutide in type 2 diabetes and chronic kidney disease randomising 576 participants over 52 weeks. Primary…
Low20 Apr 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low20 Apr 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tesamorelin in lipodystrophy over as stated in the parent protocol. The Institute holds no reported…
Very low17 Apr 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds…
Very low07 Apr 2023 -
Consultation on the policy governing the declaration and management of interests across the Institute, covering assessment committee members, external reviewers…
01 Apr 2023 -
Consultation on the policy governing what funding the Institute accepts, from whom, and on what published terms. The draft prohibits any funding arrangement that confers…
24 Mar 2023 -
Record of documents ratified in the 2023 Q1 assessment cycle.
18 Mar 2023 -
Glucose regulation impaired beyond normal limits but below diagnostic thresholds for diabetes, including impaired fasting glucose, impaired glucose tolerance, and…
16 Mar 2023 -
Degenerative joint disease of the knee with radiographic or symptomatic confirmation, occurring with obesity as a mechanical and inflammatory contributor.
09 Mar 2023
page 41 of 41